The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

Since the second version of the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015 …

Background Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is under
investigation for the treatment of Crohn's disease. Methods In two phase 3 induction trials (U …

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …

Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic
axSpA. It is a chronic inflammatory disease with a predilection for involving the axial …

Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19)
and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced …

Summary Background Upadacitinib, a Janus kinase inhibitor, has been shown to be
effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …